<!doctype html>
<html lang="en">
  <head>
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <title>How Positive Phase 3 Results for Orforglipron at Chugai Pharmaceutical (TSE:4519) Changed Its Investment Story</title>
    <meta name="description" content="Uncover how Chugai Pharmaceutical&#x27;s forecasts yield a ¥8082 fair value, a 21% upside to its current price.; This projection is based on a 4.9% annual revenue growth rate and represents a ¥121.5 billion increase in earnings from the current ¥395.4 billion.; Read the full narrative on Chugai Pharmaceutical (it&#x27;s free!) Chugai Pharmaceutical&#x27;s outlook forecasts ¥1,381.4 billion in revenue and ¥516.9 billion in earnings by 2028." />
    <link rel="alternate" type="application/rss+xml" title="Daily Finance Newsletter" href="https://suavir600.github.io/newsletter/feed.xml" />
    <style>
:root{--bg:#0b0f19;--fg:#e8ecf2;--muted:#93a1b1;--card:#121826;--accent:#4f8cff}
*{box-sizing:border-box} body{margin:0;background:var(--bg);color:var(--fg);font:16px/1.55 system-ui,-apple-system,Segoe UI,Roboto,Ubuntu}
a{color:var(--accent);text-decoration:none} a:hover{text-decoration:underline}
.container{max-width:980px;margin:0 auto;padding:20px}
.nav{display:flex;align-items:center;justify-content:space-between;margin-bottom:20px}
.brand{font-weight:700} .muted{color:var(--muted)}
.grid{display:grid;grid-template-columns:repeat(auto-fill,minmax(280px,1fr));gap:16px}
.card{background:var(--card);border-radius:16px;padding:16px;box-shadow:0 6px 20px rgba(0,0,0,.25)}
.card h3{margin:0 0 8px 0;font-size:1.05rem}
.badge{display:inline-block;background:#1c2335;color:#c0cad8;padding:.2rem .5rem;border-radius:999px;font-size:.75rem;margin-right:.4rem}
.btn{display:inline-block;background:var(--accent);color:#fff;padding:.5rem .75rem;border-radius:10px;font-weight:600}
.btn-outline{background:transparent;border:1px solid var(--accent);color:var(--accent)}
.list ul{margin:.5rem 0 0 1.2rem}
.footer{margin-top:36px;color:var(--muted);font-size:.9rem;text-align:center}
hr{border:none;border-top:1px solid #223; margin:16px 0}
</style>
  </head>
  <body>
    <div class="container">
      <div class="nav">
        <div class="brand"><a href="https://suavir600.github.io/newsletter">Daily Finance Newsletter</a></div>
        <div class="muted">5–7 key bullets per story</div>
      </div>
      
<h1>How Positive Phase 3 Results for Orforglipron at Chugai Pharmaceutical (TSE:4519) Changed Its Investment Story</h1>
<div class="muted">2025-09-08 14:15:51+00:00</div>
<hr />
<div class="list"><ul>
  <li>Uncover how Chugai Pharmaceutical&#x27;s forecasts yield a ¥8082 fair value, a 21% upside to its current price.</li><li>This projection is based on a 4.9% annual revenue growth rate and represents a ¥121.5 billion increase in earnings from the current ¥395.4 billion.</li><li>Read the full narrative on Chugai Pharmaceutical (it&#x27;s free!) Chugai Pharmaceutical&#x27;s outlook forecasts ¥1,381.4 billion in revenue and ¥516.9 billion in earnings by 2028.</li><li>How Positive Phase 3 Results for Orforglipron at Chugai Pharmaceutical (TSE:4519) Changed Its Investment Story - On August 26, 2025, Chugai Pharmaceutical reported that Eli Lilly announced positive topline Phase 3 result</li><li>Exploring Other Perspectives Two unique fair value estimates from the Simply Wall St Community range from ¥8,082 to ¥8,689 per share.</li><li>These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer&#x27;s.</li><li>The end of cancer?</li>
</ul></div>
<div style="margin-top:12px">
  <a class="btn-outline" href="https://finance.yahoo.com/news/positive-phase-3-results-orforglipron-141551068.html" target="_blank" rel="noopener">Original</a>
  <a class="btn" href="https://twitter.com/intent/tweet?text=How+Positive+Phase+3+Results+for+Orforglipron+at+Chugai+Pharmaceutical+%28TSE%3A4519%29+Changed+Its+Investment+Story%0A%E2%80%A2+Uncover+how+Chugai+Pharmaceutical%27s+forecasts+yield+a+%C2%A58082+fair+value%2C+a+21%25+upside+to+its+current+price.%0A%E2%80%A2+This+projection+is+based+on+a+4.%E2%80%A6%0Ahttps%3A%2F%2Fsuavir600.github.io%2Fnewsletter%2Farticles%2Fhow-positive-phase-3-results-for-orforglipron-at-chugai-pharmaceutical-tse-4519-%2F" target="_blank" rel="noopener">Share on X</a>
</div>

      <div class="footer">© 2025 · Built from digest_5bullets.md</div>
    </div>
  </body>
</html>